MGF is strictly for laboratory research and is commonly employed in the following investigational areas:

Satellite Cell Biology & Myogenesis

MGF is extensively utilized as a chemical probe in myology to study satellite cell dynamics. Researchers employ this peptide in myoblast cultures to quantify its dose-dependent ability to trigger cellular division, mapping the cascade required to replenish local progenitor cell pools following induced microlesions.

Mechanical Overload & Hypertrophy Models

In experimental models simulating mechanical tension or tissue strain, MGF is used to study the autocrine signaling pathways that govern biomechanical adaptation. Assays focus on how the expression of the MGF E-domain mediates localized cellular hypertrophy and structural remodeling independent of the systemic somatotropic axis.

Neuroprotection and Cellular Ischemia

Beyond skeletal muscle, MGF expression has been identified in the central nervous system following ischemic events. Neurobiological research employs synthetic MGF to investigate its neuroprotective effects, focusing on how the peptide modulates survival pathways and reduces cellular apoptosis in brain ischemia models.

Pathway / Mechanistic Context

The primary mechanism of action for MGF in research settings involves distinct intracellular signaling divergent from standard IGF-1 pathways.

• Receptor Independent Activation: MGF utilizes a unique, yet-to-be-fully-characterized receptor mechanism driven by its C-terminal E-domain, operating independently of the classic IGF-1 receptor.
• Signal Transduction: Binding triggers the rapid and transient activation of the MEK/ERK1/2 (mitogen-activated protein kinase) signaling cascade.
• Resulting Flux: The activation of the ERK pathway strongly promotes cellular proliferation (mitogenesis) and transiently inhibits differentiation factors (like MyoD). This preserves the cells in a proliferative state, ensuring an adequate pool of satellite cells is generated before mature IGF-1 directs them to fuse and repair damaged tissue.

Preclinical Research Summary

Published preclinical literature documents investigations of MGF across multiple experimental models:

• Tissue Repair: In vitro studies using primary muscle cell cultures demonstrate that the addition of MGF significantly enhances the proliferation rate of satellite cells compared to mature IGF-1 treatment alone.
• Genetic Splicing Assays: Research confirms that mechanical stimulation of muscle tissue induces a splice shift in the IGF-1 gene towards the MGF (IGF-1Ec) isoform, confirming its role as an immediate-early mechanosensitive gene product.
• Ischemic Protection: Data from in vivo neurological assays show that delivery of the MGF C-terminal peptide significantly reduces neuronal loss and infarct volume when administered during the acute phase of cerebral ischemia.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Goldspink, G. (2005). Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda, Md.), 20(4), 232-238. https://doi.org/10.1152/physiol.00004.2005
• Yang, S., Alnaqeeb, M., Simpson, H., & Goldspink, G. (1996). Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. Journal of Muscle Research and Cell Motility, 17(4), 487-495. https://doi.org/10.1007/BF00123364
• Mills, P., et al. (2007). Differential expression of the IGF-I splice variants MGF and IGF-IEa in response to microlesions in muscle. Growth Hormone & IGF Research, 17(4), 302-310.https://pmc.ncbi.nlm.nih.gov/articles/PMC2342624/
• Dluzniewska, J., et al. (2005). A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. The FASEB Journal, 19(13), 1896-1898. https://doi.org/10.1096/fj.05-3786fje

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.